PROMISE TRIAL:
RESULTS OF CONTINUED VS DISCONTINUED ART
AFTER END OF BREASTFEEDING

Taha E. Taha, Sean Brummel, Konstantia Angelidou, Mary Glenn Fowler, Patricia Flynn, Cornelius Mukuzunga, Dingase Dula, Maxensia Owor, Dhayendre Moodley, Tsungai Chipato, Amy James Loftis, Nahida Chakhtoura, Katie McCarthy, Judith Currier, for the IMPAACT PROMISE Study Team
INTRODUCTION

• The PROMISE multi-country randomized trial showed that use of triple antiretroviral drug regimens antepartum and postpartum substantially reduce transmission of HIV from HIV-infected mothers to their children.

• As use of antiretroviral treatment (ART) becomes universal, evaluation of extended use remains important.

• This analysis, part of the PROMISE Maternal Health (MH) component, compares efficacy and safety between women who were randomized to continue or discontinue use of combined ART after cessation of risk of mother-to-child transmission (MTCT) of HIV during breastfeeding.
METHODS

• This randomized trial, comprising eligible HIV-infected women from the postpartum component of PROMISE trial, was conducted during the period November 2011 and September 2014.

• Women who were originally randomized to triple ART for prevention of MTCT and maintained CD4 cell counts ≥ 350 cells/mm³ were randomized at the end of breastfeeding risk (cessation of breastfeeding) to two study arms: continue with use of ART or discontinue use of ART. Women who needed ART for their own health were not randomized.
What is the effect of extending the postpartum maternal triple ARV regimen after cessation of BF versus discontinuing the regimen with cessation of BF?
Study procedures at scheduled visits included completion of study forms, physical examination and collection of samples to perform laboratory tests – including hematology, chemistry, CD4 count, and viral load.

Women randomized to continue ART were provided with lopinavir-ritonavir plus a fixed dose combination of emtricitabine-tenofovir disoproxil fumarate as the preferred regimen.

Women who became pregnant were followed during the study and continued to receive combined ART as part of the study with modifications as necessary.

Women in the discontinue ART arm received the local standard of care during follow-up. Women re-started ART for their own health, if needed.
METHODS (CONT.)

• The primary study efficacy endpoint was a composite measure of progression to AIDS-defining illness (WHO stage IV clinical event) or death.

• An Endpoint Review Committee reviewed all diagnoses identified as potential endpoints.

• Secondary safety outcome: Grade 3 or greater laboratory results or signs and symptoms and selected Grade 2 renal and hepatic laboratory results.

• An intent-to-treat analyses based on the randomization study arms was used.
METHODS (CONT.)

• The analyses are based on data collected before July 7, 2015 when the study sites were instructed to offer ART to all participants based on new findings from another study (START trial).

• Comparisons for categorical outcomes used Fisher’s exact test.

• Comparisons between randomization arms with a survival outcome used the log-rank test and Cox regression models for estimation of treatment effect sizes.

• Time to event distributions were summarized using Kaplan-Meier (K-M) estimators.

• Incidence rates were calculated per 100 person-years (PYs).
• In total, 557 women were randomized: 289 to continue ART and 268 to discontinue ART from the following sites: Malawi (33%), Zimbabwe (25%), South Africa (21%), Uganda (13%), India (7%), Tanzania (1%), and Zambia (1 participant).

• Baseline characteristics were similar at randomization: most women were black Africans (94%); median age was 28 years; BMI was 23.1 kg/m²; most were WHO clinical stage I (93%); and the majority had a CD4 $>500$ cells/mm³ (95%).

• The overall median follow-up was 84 weeks (range: 4-171) and was not different between the two arms:
  Follow-up (person-years sum of values): 438.4 in continue ART arm
  433.0 weeks in discontinue ART arm
RESULTS (CONT.)

• **Primary efficacy comparisons**: There were **two maternal deaths**, one in each arm. The rates were comparable and not statistically significant; hazard ratio=1.04 (95% CI 0.06-16.59).

• Reported causes of death: Continue ART - ruptured ectopic pregnancy; Discontinue ART - chronic renal insufficiency.
### Primary Efficacy: Time to first AIDS-defining illness or death

<table>
<thead>
<tr>
<th>Randomization Arm</th>
<th>Incidence rate (95% CI)</th>
<th>Hazard ratio (95% CI)</th>
<th>Log Rank p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continue triple ARV</td>
<td>0.23 (0.15, 0.34)</td>
<td>1.04 (0.06, 16.59)</td>
<td>0.98</td>
</tr>
<tr>
<td>Discontinue triple ARV</td>
<td>0.23 (0.16, 0.35)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

![Graph showing estimated probability over time for different randomization arms](image-url)
RESULTS – SAFETY

• **Secondary safety comparisons:** There were 78 composite safety events in the continue arm and 57 in the discontinue arm (p-value = 0.08).

• **Restricting the analysis to only signs and symptoms:** There were 20 grade 3 or higher signs and symptoms in the continue arm and 7 in the discontinue arm (p-value = 0.01). The most common sign and symptom was weight loss: 16 in continue arm and 5 in discontinue arm.
Time to first grade 2, 3 or 4 adverse events – Composite endpoint of Chemistries, Signs and Symptoms

<table>
<thead>
<tr>
<th>Randomization arm</th>
<th>Subjects</th>
<th>Cumulative events</th>
<th>Total person - Years</th>
<th>Incidence rate (95% CI) *</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuation triple ARV</td>
<td>289</td>
<td>78</td>
<td>359.1</td>
<td>21.7 (17.1, 27.7)</td>
<td>0.08</td>
</tr>
<tr>
<td>Discontinue triple ARV</td>
<td>267</td>
<td>57</td>
<td>356.1</td>
<td>16.0 (12.1, 21.3)</td>
<td></td>
</tr>
</tbody>
</table>
## Time to first grade 3 or 4 signs or symptoms

<table>
<thead>
<tr>
<th>Randomization arm</th>
<th>Subjects</th>
<th>Cumulative events</th>
<th>Total person - Years</th>
<th>Incidence rate (95% CI) *</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuation triple ARV</td>
<td>289</td>
<td>20</td>
<td>408.9</td>
<td>4.9 (3.8, 6.3)</td>
<td>0.01</td>
</tr>
<tr>
<td>Discontinue triple ARV</td>
<td>267</td>
<td>7</td>
<td>411.3</td>
<td>1.7 (1.1, 2.6)</td>
<td></td>
</tr>
</tbody>
</table>
• Of the 557 women in this analysis, 81 (15%) had a record of at least one subsequent pregnancy, 42 in continue ART arm and 39 discontinue ART arms:

<table>
<thead>
<tr>
<th>Delivery Outcome</th>
<th>Continue arm N=42</th>
<th>Discontinue arm N=39</th>
<th>Total N=81</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live birth</td>
<td>28 (67%)</td>
<td>28 (72%)</td>
<td>56</td>
</tr>
<tr>
<td>Induced abortion</td>
<td>6 (14%)</td>
<td>5 (13%)</td>
<td>11</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>4 (10%)</td>
<td>2 (5%)</td>
<td>6</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>2 (5%)</td>
<td>2 (5%)</td>
<td>4</td>
</tr>
<tr>
<td>Live birth followed by neonatal death</td>
<td>1 (2%)</td>
<td>1 (3%)</td>
<td>2</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

These differences were not statistically significant (p=0.59)
## RESULTS – SUMMARY

<table>
<thead>
<tr>
<th></th>
<th>Rates of Adverse Events per 100 PY</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Continue ART</td>
<td>Discontinue ART</td>
</tr>
<tr>
<td><strong>Primary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIDS defining illness or death*</td>
<td>0.23 (1/435.1)</td>
<td>0.23 (1/430.5)</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composite grade 2, 3 or 4 adverse events**</td>
<td>21.7 (78/359.1)</td>
<td>16.0 (57/356.1)</td>
</tr>
<tr>
<td>Composite grade 3 or 4 serious adverse events***</td>
<td>9.7 (38/391.4)</td>
<td>5.5 (22/400.3)</td>
</tr>
<tr>
<td>Grade 3 or 4: signs or symptoms***</td>
<td>4.9 (20/408.9)</td>
<td>1.7 (7/411.3)</td>
</tr>
<tr>
<td>Grade 2, 3, 4 hematology or chemistry***</td>
<td>15.4 (57/370.9)</td>
<td>12.3 (45/365.1)</td>
</tr>
<tr>
<td>Composite endpoint of HIV/AIDS-related event or WHO stage II/III event**</td>
<td>4.28 (18/420.2)</td>
<td>2.37(10/422.8)</td>
</tr>
</tbody>
</table>

* Pre-specified analysis: only two deaths; no AIDS-defining illness. ** Pre-specified secondary outcome; *** Post-hoc analysis
After cessation of breastfeeding, rates of clinical events remained very low in both groups. However, the rates of some secondary post-hoc AE analyses were significantly higher in the continue ART arm compared to discontinue ART arm. Studies of newer ART regimens are needed to improve the long-term outcomes for post-partum women.
Acknowledgements

The PROMISE Protocol Team gratefully acknowledges the dedication and commitment of the more than 3,500 mother-infant pairs without whom this study would not have been possible.

Sponsors:
US National Institutes of Health (D Gnanashanmugam, K Klingman, R Browning, L Purdue, N Chakhtoura, G Siberry, LM Mofenson)
AbbVie, Gilead Sciences, Boehringer Ingelheim, ViiV/GlaxoSmithKline

Protocol Chair and Vice Chairs:
MG Fowler, J McIntyre, T Chipato, P Flynn, J Currier

Operations Center:
M Allen, A Coletti, K George, M Valentine, K McCarthy, V Toone

Statistical and Data Management Center:
D Shapiro, T Fenton, K Butler, M Qin, C Marr, C Tierney, S Brummel, K Angelidou, M Basar, L Marillo, A Manzella, A Zadzilka

Laboratory Center:
S Fiscus, A Loftis

CMC:
J McIntyre, L Stranix, D Battacharya, R Hoffman, A Gupta, G Theron, B Chi, P Flynn, M Owor, JS Currier

Site PROMISE Principal Investigators:

India:
BJMC, Pune: R Bhosale, P Sambarey

Malawi:
Blantyre: B Makanani, M Mallewa
UNC-Lilongwe: M Martinson, M Hosseinipour, L Chinula

South Africa:
CAPRISA Umlazi, Durban: D Moodley
Durban Paeds, Durban: R Bobat, S Pillay
FAM-CRU, Stellenbosch: G Theron
PHRU, Soweto: A Violari
Shandukani, Johannesburg: L Fairlie, A Coovadia

Tanzania:
KCSC, Moshi: P Mlay

Uganda:
MU-JHU, Kampala: M Owor, M Kamateeka, J Aizire

Zambia:
George Clinic, Lusaka: M Mbewe, B Chi

Zimbabwe:
St. Mary’s, Seke North, and Harare Family Care: T Chipato, L Stranix
PROMISE 1077BF/1077FF is funded by the US National Institutes of Health (NIH). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The study products were provided free of charge by AbbVie, Gilead Sciences, Boehringer Ingelheim, and ViiV/GlaxoSmithKline.